III期非小细胞肺癌放化疗后度伐利尤单抗巩固治疗对比无巩固治疗的成本效果与预算影响分析:美国医疗体系背景
该研究采用决策分析微观模拟模型,比较III期不可切除非小细胞肺癌放化疗后度伐利尤单抗巩固治疗与无巩固治疗两种策略。
要点
- 在10万美元/质量调整生命年支付阈值下,度伐利尤单抗巩固治疗对比无巩固治疗具有成本效果。
- 估计增量成本效果比为67,421美元/质量调整生命年。
核心结论
- 度伐利尤单抗巩固治疗在III期非小细胞肺癌中具有成本效果,尽管预算影响显著。
- 在癌症进展早期使用免疫治疗可提供显著价值。
研究设计与样本
- 决策分析微观模拟模型,在学术医疗环境中开发。
- 比较放化疗后无巩固治疗直至进展与度伐利尤单抗巩固治疗直至进展或最长1年两种策略。
关键数值与推荐
- 在100,000美元/质量调整生命年支付阈值下,度伐利尤单抗巩固治疗具有成本效果。
- 增量成本效果比为67,421美元/质量调整生命年。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In early 2018, durvalumab became the first immunotherapy to be approved for adjuvant treatment of patients with unresectable stage III non-small cell lung cancer (NSCLC) whose cancer has not progressed after definitive chemoradiotherapy. However, the cost-effectiveness and potential economic implications of using this high-priced therapy in this indication are unknown to date. OBJECTIVE: To explore the cost-effectiveness and potential budgetary consequences of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III NSCLC in the context of the US health care system. DESIGN, SETTING, AND PARTICIPANTS: A decision analytic microsimulation model was developed in an academic medical setting to compare the following 2 postchemoradiotherapy strategies: all patients receive no consolidation therapy until progression vs all patients receive durvalumab consolidation therapy until progression or for a maximum of 1 year. The potential budgetary consequence was calculated by applying the proportion of patients with NSCLC who were diagnosed in stage III and received chemoradiotherapy to the projected number of annual new cases for 2018 to 2022 to find total eligible patients and then multiplied by the mean difference in annual cost between the strategies over this 5-year period. Simulated conditions were matched to those of the PACIFIC phase 3 randomized clinical trial and reasonable treatment strategies for metastatic NSCLC. All simulated patients begin disease free after having received radical treatment with chemoradiotherapy and are followed up as they progress to metastatic disease first-line treatment, metastatic disease second-line treatment, end-stage progressive disease, and death. MAIN OUTCOMES AND MEASURES: The main outcome of this study was the incremental cost-effectiveness ratio of durvalumab consolidation therapy vs no consolidation therapy, given as aggregate cost of treatment per quality-adjusted life-year gained. RESULTS: Among 2 million simulated patients, durvalumab consolidation therapy was cost-effective compared with no consolidation therapy at a $100 000 per quality-adjusted life-year willingness-to-pay threshold, with an estimated incremental cost-effectiveness ratio of $67 421 per quality-adjusted life-year, and would contribute an additional $768 million to national cancer spending in year 1. The annual budgetary consequence would then decrease to $241 million in year 5. CONCLUSIONS AND RELEVANCE: Durvalumab consolidation therapy represents an indication where expensive immunotherapies can be cost-effective. Treating with immunotherapy earlier in the course of cancer progression can provide significant value, despite having a substantial budgetary consequence.
引用
- Criss SD, Mooradian MJ, Sheehan DF, et al. Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System. JAMA Oncol. 2019. PMID: 30543349. doi:10.1001/jamaoncol.2018.5449
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。